Obinutuzumab for cryoglobulinemia vasculitis after rituximab failure
Treatments studied
Part of Blood & lymphatic, Immune system & allergy clinical trials.
This trial tests if the drug obinutuzumab can help people with a blood vessel inflammation called cryoglobulinemia vasculitis when rituximab no longer works or causes side effects. It is a single-arm study, meaning everyone gets the new drug.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You must be 18 years or older.
- You must have active vasculitis (inflammation of blood vessels) from cryoglobulinemia.
- You must have tried rituximab and it either did not work well enough or you had to stop due to side effects.
- You must not have other reasons for vasculitis, active infections, or recent cancer.
- You must agree to use effective birth control if you could become pregnant, and not be pregnant or breastfeeding.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This Phase 2 study tests belimumab (or a placebo) to see if it improves safety and disease control in adults with active cryoglobulinemia vasculitis. You may be eligible if you have had rituximab induction treatment shortly before joining, and your illness is still active.
This trial tests a new drug called obinutuzumab for adults whose nephrotic syndrome (a kidney disease causing swelling and protein in urine) has relapsed after stopping rituximab. It aims to see if obinutuzumab can help prevent future relapses.
This trial tests a drug called obinutuzumab to see if it can help people whose vasculitis (inflammation of blood vessels) has come back after previous treatment. It is designed for people with a specific type of vasculitis that affects small blood vessels and is linked to PR3-ANCA antibodies.
This trial tests whether obinutuzumab, a targeted therapy that quiets certain immune cells, can reduce kidney damage in people with fibrillary glomerulonephritis. If you have this rare kidney condition and significant protein in your urine, this study may offer a new treatment option.
This study compares two antibody medicines, obinutuzumab and rituximab, to prevent relapses of steroid-dependent or frequently relapsing nephrotic syndrome in children. It looks at whether one option works better and is safer, including infection risk.
This trial tests a drug called obinutuzumab for people with chronic ITP (low platelets) who haven't gotten better with steroids. The goal is to see if it can safely raise your platelet count.
Hear when a new Cryoglobulinemic Vasculitis (CV) trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.